

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Serial No.:	10/701,041
Applicant:	Benjamin OSHLACK et al.
Filed:	November 4, 2003
Art Unit:	1616
Examiner:	James Henry ALSTRUM ACEVEDO
For:	TAMPER-RESISTANT ORAL OPIOID AGONIST FORMULATIONS

Mail Stop: AMENDMENT
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

October 1, 2009

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Sir:

In accordance with Applicants' duty of disclosure under 37 C.F.R. § 1.56 and the provisions of 37 C.F.R. §§ 1.97 and 1.98, Applicants submit herewith copies of:

- (i) the Office Action issued on July 20, 2009, in U.S. Serial No. 10/700,861; and
- (ii) the Office Action issued on July 22, 2009, in U.S. Serial No. 10/689,866.

It is respectfully requested that the information in the Office Actions be considered in its entirety and made of record.

This Information Disclosure Statement is filed under 37 C.F.R. § 1.97(c), "before the mailing date of any of a final action under § 1.113, a notice of allowance under § 1.311, or an action that otherwise closes prosecution in the application" and is accompanied by the authorization to charge the fee set forth in § 1.17(p) to our Deposit Account No. 50-0552. In the


200.1133CON2

event any additional fee is due or an overpayment has been made in connection with the filing of this Information Disclosure Statement, the Commissioner is hereby authorized to charge said fee or credit said overpayment to our Deposit Account No. 50-0552.

Respectfully submitted,

DAVIDSON, DAVIDSON & KAPPEL, LLC

By:



Oleg Ioselevich

Reg. No. 56,963

DAVIDSON, DAVIDSON & KAPPEL, LLC
Patents, Trademarks and Copyrights
485 Seventh Avenue, 14th Floor
New York, New York 10018
(212) 736-1940